Axinesis said today it won CE Mark approval in the European Union for its REAPlan medical interactive robot device designed to rehabilitate impaired upper limbs in stroke victims and children with cerebral palsy.
The Belgian company’s REAPlan combines robotics and “therapeutic gaming” to improve rehabilitation of impaired upper limbs, and offers automated personalized assistance of arm movements, Axinesis said.
“This is an important milestone in our mission to provide state-of-the-art technologies dedicated to the rehabilitation of brain-injured patients. The continual requests from customers for products enhancing patients’ rehabilitation, and the feedbacks of users on this project have been exceptional. We are very pleased to offer an innovative high-end technology, for a very affordable investment, to the European rehabilitation community and expand the clinical options available to all. Robotics, integrated in rehabilitation programs, enable stroke patients to accomplish significant numbers of moves with their arms, fostering a natural reconstruction process of the brain, called neuroplasticity. Based on our current data and results, REAplan can help over 5 million people worldwide, left permanently disabled after a stroke event, as well as children affected by the most common childhood disability, cerebral palsy,” CEO Eric Hanesse said in prepared remarks.
Axinesis’ REAPlan optimizes the process of neuronal reorganization, known as neuroplasticity, through intense repeated movements for patients with brain injuries and motor development in children with cerebral palsy, the company claims.
The company’s device has been evaluated after use with more than 300 patients, the company said. Axinesis said it is positioned to begin immediate sales and distribution in select European Union countries.